Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: Mechanistic insight from studies of 3-methyl-1,2,4- benzotriazine 1,4-dioxide

Journal of the American Chemical Society

Volumn 131, Issue 3, 2009, Pages 1015-1024

  Junnotula, Venkatraman ^a   Sarkar, Ujjal ^a   Sinha, Sarmistha ^a   Gates, Kent S ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR AGENTS; ANTITUMOR DRUGS; BENZOTRIAZINYL RADICAL; CHEMICAL MECHANISM; DNA DAMAGES; DNA DAMAGING AGENTS; DNA STRANDS; ENZYMATIC REDUCTION; HOMOLYSIS; HYDROXYL RADICALS; HYPOXIC CELLS; HYPOXIC CONDITION; ISOTOPIC LABELING; NEW CLASS; O-H BOND; ONE-ELECTRON REDUCTIONS; ORGANIC SUBSTRATE; SELECTIVE OXIDATION; SOLID TUMORS; TIRAPAZAMINE;

AMINES; GENES; LABELS; NUCLEIC ACIDS; OXYGEN;

DNA;

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; 3 METHYL 1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; ANTINEOPLASTIC AGENT; TIRAPAZAMINE; UNCLASSIFIED DRUG; DNA; FREE RADICAL; TRIAZINE DERIVATIVE;

ARTICLE; DNA CLEAVAGE; DNA DAMAGE; DNA STRAND; DRUG STRUCTURE; OXIDATION REDUCTION REACTION; REDUCTION; CELL HYPOXIA; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METHYLATION;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; DNA; DNA CLEAVAGE; FREE RADICALS; METHYLATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; TRIAZINES;

EID: 61749095311     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja8049645     Document Type: Article

References (23)

1. Marco, L.; Olver, I. Curr. Clin. Oncol. 2006, 1, 71-79.
2. Horsman, M. R. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 701-704.
3. Siemann, D. W. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 697-699.
4. Vaupel, P.; Kallinowski, F.; Okunieff, P. Cancer Res. 1989, 49, 64496465.
5. Wilson, W. R. Tumour hypoxia: challenges for cancer chemotherapy. In The Search For New Anticancer Drugs; Waring, M. J., Ponder, B. A. J., Eds.; Kluwer Academic: Lancaster, 1992; pp 87-131.
6. Brown, J. M.; Wilson, W. R. Nat. Rev. Cancer 2004, 4, 437-447.
7. Brown, J. M. Cancer Res. 1999, 59, 5863-5870.
8. Zeman, E. M.; Brown, J. M.; Lemmon, M. J.; Hirst, V. K.; Lee, W. W. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12, 1239-1242.
9. Laderoute, K. L.; Wardman, P.; Rauth, M. Biochem. Pharmacol. 1988, 37, 1487-1495.
10. Wardman, P.; Priyadarsini, K. I.; Dennis, M. F.; Everett, S. A.; Naylor, M. A.; Patel, K. B.; Stratford, I. J.; Stratford, M. R. L.; Tracy, M. Br. J. Cancer 1996, 74, S70-S74.
11. Priyadarsini, K. I.; Tracy, M.; Wardman, P. Free Radical Res. 1996, 25, 393-399.
12. Poole, J. S.; Hadad, C. M.; Platz, M. S.; Fredin, Z. P.; Pickard, L.; Guerrero, E. L.; Kessler, M.; Chowdhury, G.; Kotandeniya, D.; Gates, K. S. Photochem. Photobiol. 2002, 75, 339-345.
13. 2̇-) produced by this type of redox cycling can be cytotoxic, see refs 14-19. However, cellular enzymes including superoxide dismutase, catalase, glutathione peroxidase, and peroxire- doxins mitigate the deleterious effects of superoxide radical and its decomposition products (see refs 18, 20, and 21.) and, in the context of TPZ, back-oxidation of 2 clearly represents a detoxification process.
14. Chen, Y.; Jungsuwadee, P.; Vore, M.; Butterfield, D. A.; St Clair, D. K. Mol. Interv. 2007, 7, 147-156.
15. Halliwell, B.; Gutteridge, J. M. C. Methods Enzymol. 1990, 186,185.
16. Bagley, A. C.; Krall, J.; Lynch, R. E. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 9189-9193.
17. SánchezSellero, I.; Lopez-RivadullaLamas, M. Recent Res.Dev.Drug Metab. Disp. 2002, 1, 275-313.
18. Finkel, T.; Holbrook, N. J. Nature 2000, 408, 239-247.
19. Davis, W., Jr.; Ronai, Z.; Tew, K. D. J. Pharm. Exp. Ther. 2001, 296, 1-6.
20. Sies, H. Angew. Chem., Int. Ed. Engl. 1986, 25, 1058-1071.
21. Wood, Z. A.; Poole, L. B.; Karplus, P. A. Science, 300, 650-653.
22. Kotandeniya, D.; Ganley, B.; Gates, K. S. Bioorg. Med. Chem. Lett. 2002, 12, 2325-2329.
23. Birincioglu, M.; Jaruga, P.; Chowdhury, G.; Rodriguez, H.; Dizdaroglu, M.; Gates, K. S. J. Am. Chem. Soc. 2003, 125, 11607-11615.